Trial · NCT07889843
Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
NCT07889843, Recruiting, Hellenic Cooperative Oncology Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer. Trials, record NCT07889843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
- NCT number
- NCT07889843
- Status
- Recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Conditions
- High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | FRα-Positive Status | Baseline | Assessment of FRα-positive status at diagnosis, defined as ≥75% of viable tumor cells demonstrating moderate (2+) and/or strong (3+) membrane staining by immunohistochemistry. |
| Secondary | FRα expression | Baseline | Qualitative assessment of FRα expression in tumor samples at diagnosis based on immunohistochemical staining intensity (2+ and 3+) and distribution across viable tumor cells. |
| Secondary | FRα expression levels | Baseline | Assessment of FRα expression levels categorized according to the percentage of viable tumor cells showing moderate (2+) and/or strong (3+) membrane staining, grouped into predefined categories (0-24%, 25-49%, 50-74%, and ≥75%). |
| Secondary | FRα expression levels and PFS/OS | From initiation of first-line treatment until disease progression, death, or last follow-up, whichever occurs first (for PFS); and until death from any cause or last follow-up (for OS), assessed up to 120 months | Evaluation of the association between FRα expression levels (0-24%, 25-49%, 50-74%, ≥75%) and clinical outcomes, including progression-free survival (PFS) and overall survival (OS). |
| Secondary | FRα expression score | Baseline | Quantitative assessment of FRα expression as a continuous variable, defined as the percentage of viable tumor cells demonstrating moderate (2+) and/or strong (3+) membrane staining. |
| Secondary | FRα expression score and BRCA/HRD status | Baseline | Assessment of the association between FRα expression score and tumor molecular status, including BRCA mutation status and homologous recombination deficiency (HRD), in samples obtained at diagnosis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889843
GET https://conductscience.org/api/trials/v1/NCT07889843/registered